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The synthetic proteinase inhibitor, FUT-175 (6-amidino-2-naphthyl-4-guanidinobenzoate), strongly 
suppressed activation of Clr at 37”C, causing 50% inhibition at 0.03 mM. To clarify whether the inhibitor 
was incorporated into the active site of intermediary Clr formed during the incubation, determination of 
the active site was tried using this inhibitor. Consequently, release of amidinonaphthol equimolar with the 
amount of Clr used was observed in the early period of incubation, in which the activation to Clrwas about 
5%. These results indicate that intermediary Clr already has a complete active site. 
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1. INTRODUCTION 
The first component of complement, Cl, con- 
sists of 3 subcomponents, Clq, Clr and Cls, which 
form a complex in the presence of Ca2+ (11. When 
Cl binds to the immune complex via Clq, Clr pro- 
enzyme is converted into an active proteinase, 
which catalyzes the proteolytic activation of Cls 
[2]. The most interesting problem in the Cl activa- 
tion mechanism is how the Clr proenzyme is ac- 
tivated upon binding of Clq to the immune com- 
plex [3-61. 
Although there are some inconsistencies in inter- 
pretation of the activation mechanism, the activa- 
tion of Clr has been generally accepted to be an 
autocatalytic reaction [7-141. Furthermore, sever- 
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al workers speculated that the proteolytic site for 
activation of Clr is generated in the Clr proenzyme 
through a conformational change [8,9,15]. Recent- 
ly, direct proof of the conformational change of 
Clr during the activation process at 37°C was ob- 
tained using a hydrophobic fluorescent probe [ 161. 
However, the relation between conformational 
change of Clr and active site formation is still not 
clear. 
Recently, we developed a new synthetic pro- 
teinase inhibitor, FUT-175 [ 171. This inhibitor 
strongly inhibits almost all serine proteinases in- 
volved in coagulation, kallikrein-kinin, fibrino- 
lysis and complement systems. To clarify the in- 
teresting problem of the relation between the con- 
formational change and active site formation, we 
tested the effect of this inhibitor on activation of 
Clr, and examined whether the possible active site 
formed with a conformational change of Clr could 
be determined using the inhibitor. 
2. MATERIALS AND METHODS 
The following reagents were obtained commer- 
cially: leupeptin (Protein Research Foundation, 
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Japan), DFP (Katayama, Japan), NPGB-HCl 
(Sigma, MO), Sepharose 6B and CM-Sephadex 
C-50 (Pharmacia, Sweden), BioGel A-l.5 m (Bio- 
Rad, USA). Human fresh frozen plasma was ob- 
tained from the Japan Red Cross. FUT-175 and 
acetylglycyl-L-lysine a-naphthyl ester were pre- 
pared in the Research Laboratories of Torii & CO., 
Japan. 
2.1. Complement component 
Clr was isolated as in [6] with extensive 
modifications. A sample of 1000 ml human serum 
containing 1 mM DFP, 100 mg soybean trypsin in- 
hibitor and 3 mM benzamidine was diluted with 4 1 
cold water containing the above inhibitor, allowed 
to stand overnight at 4”C, and then centrifuged. 
The small precipitate of euglobulin was partially 
dissolved by addition of 15 ml of 50 mM acetate 
buffer (pH 5.5), containing 200 mM NaCl, 5 mM 
CaClz and 1 mM DFP, and centrifuged for 60 min 
at 105000 x g. The supernatant was fractionated 
on a column (5 x 90 cm) of Sepharose 6B in the 
same buffer. Active fractions were pooled, treated 
with FDP at a final concentration of 1 mM, con- 
centrated to 100 ml by ultrafiltration and dialyzed 
against 50 mM acetate buffer (pH 5.5), containing 
50 mM NaCl and 5 mM EDTA. The dialyzate was 
applied to a CM-Sephadex C-50 column (2.5 x 
10 cm) equilibrated with the same buffer and 
material was eluted with a linear gradient of 
50-500 mM NaCl in 2000 ml starting buffer. Ac- 
tive fractions were pooled, concentrated and ap- 
plied to BioGel A-l.5 m in 50 mM acetate buffer 
(pH 5.5) containing 500 mM NaCl and 5 mM 
EDTA. About 4 mg purified Clr was obtained by 
these procedures and stored at - 70°C before use. 
For detection of Clr, 10-20~1 of each fraction 
was incubated with 700 ~1 of 100 mM phosphate 
buffer (pH 7.0), and 100 ,ul of 0.01% trypsin solu- 
tion in the same buffer for 5 min at 37°C. Then the 
trypsin was neutralized by addition of 100 ~1 of 
0.5% soybean trypsin inhibitor solution in the 
same buffer. The esterase activity of Clr after tryp- 
sin treatment was determined with 0.2rmol 
acetylglycyl-L-lysine a-naphthyl ester as substrate 
[ 181. The purified Clr proenzyme gave a single pro- 
tein band with an apparent M, of 88000 on 
SDS-PAGE in the reduced form, while after in- 
cubation at 37°C heavy and light chains with ap- 
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parent M, values of 55000 and 35 000 appeared 
under reducing conditions. 
2.2. SDS-PAGE 
Electrophoresis was done in 7% polyacrylamide 
gel under reducing conditions as in [ 191. Samples 
of 8.8 pg Clr in 125 mM Tris buffer (pH 7.4) con- 
taining 1.5 mM CaC12 and 150 mM NaCl were in- 
cubated for 60 min at 37°C with or without 
various inhibitors in a total volume of 40 ~1. Then 
the samples were heated for 5 min at 80°C with 
1% SDS and 2% 2-mercaptoethanol and analyzed 
by SDS-PAGE. The extent of Clr activation was 
monitored densitometrically (Toyo digital den- 
sitorol DMU-33C) after staining the protein with 
Coomassie brilliant blue. 
2.3. Fluorescence measurement 
The active site was determined by measuring the 
fluorescence of amidinonaphthol released in the 
enzyme reaction, using FUT-175. A mixture of 
100,~l Clr (0.57 nmol) in 125 mM Tris buffer (pH 
7.4) containing 1.5 mM CaClz and 150 mM NaCl 
(ice-cold), 380 ~1 of the same buffer (prewarmed to 
37°C) and 20~1 FUT-175 (57 nmol) in distilled 
water (ice-cold) was rapidly mixed in a cell and 
promptly incubated at 37°C. Release of 
amidinonaphthol was monitored in a Hitachi 
fluorescence spectrophotometer, model 650-lOM, 
using excitation and emission wavelengths of 330 
and 480 nm, respectively. The control mixture was 
the same, but without enzyme. The fluorescence of 
amidinonaphthol released with enzyme minus that 
released without enzyme was defined as the 
amount of active site. Under these conditions, the 
fluorescence intensity of amidinonaphthol was 
stable and no fluorescence of FUT-175 itself was 
observed. The extent of activation of Clr without 
FUT-175 under the same conditions was analyzed 
by SDS-PAGE as described above. 
2.4. Protein determination 
Clr was measured from its absorbance at 280 nm 
using &I% = 11.2 [12]. 
3. RESULTS 
3.1. Effect of FUT-I 75 on activation of Clr 
at 37°C 
The inhibitory effects of FUT-175 and other in- 
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hibitors on the activation of Clr at 37°C were in- 
vestigated, and results are illustrated in fig.1. The 
most potent inhibitor was FUT-175 which, at 
0.03 mM, caused 50% inhibition. Although 
NPGB was also strongly inhibitory, its effect was 
l/5 that of FUT-175 (0.15 mM). DFP and leupep- 
tin were active at higher concentrations (3.1 and 
1.7 mM, respectively). These results suggest hat 
these inhibitors may be incorporated into Clr pro- 
enzyme, and consequently suppress the activation 
to Cl;. The differences in the effects of these in- 
hibitors may result from differences in their ac- 
cessibilities to the active site. To investigate 
whether the active site is actually formed in Clr 
proenzyme and whether the inhibitor is incor- 
porated into the active site, we tried to determine 
the active site formed in Clr proenzyme using 
FUT-175, which was the most effective inhibitor of 
activation of Clr. 
3.2. Determination of the active site of Clr 
proenzyme using FUT-175 
Fig.2 shows the amount of amidinonaphthol 
released from FUT-175 in the enzyme reaction of 
Clr proenzyme during incubation at 37°C. As can 
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Fig. 1. Effects of various inhibitors on Clr activation. Clr 
(220pg/ml) was incubated in 125 mM Tris buffer (pH 
7.4) containing 1.5 mM CaCl2 and 150 mM NaCl for 
60 min at 37”C, in the presence of FUT-175 (o), NPGB 
(o), DFP (A) or leupeptin ( q ) at final concentrations of 
0.001-l mM (FUT-175 and NPGB) or 0.1-10 mM 
(DFP and leupeptin). After reduction, samples were 
analyzed by SDS-PAGE, and the amount of Cl; was 
determined by scanning the gels after staining with 
Coomassie blue. 
- 0.6. 
+ 
Incubation Time ( min 1 
Fig.2. Determination of the active site of Clr. A mixture 
of Clr (0.57 nmol) and FUT-175 (57 nmol) was 
incubated in 500~1 125 mM Tris buffer, containing 
1.5 mM CaClz and 150 mM NaCl. The fluorescence of 
amidinonaphthol released was monitored in a Hitachi 
fluorescence spectrophotometer using excitation and 
emission wavelengths of 330 and 480 nm, respectively. 
The extent of activation to Clr in the absence of 
FUT-175 was analyzed by SDS-PAGE, as described for 
fig.1. 
be seen, the release of amidinonaphthol gradually 
increased during incubation at 37”C, and after 
about 10 min amidinonaphthol was released in an 
amount equimolar to that of Clr used. On the 
other hand, the rate of activation to Clf after 
10 min incubation in the absence of FUT-175 was 
about 5%. These results strongly suggest hat the 
proenzyme Clr (single chain) with a complete ac- 
tive site appeared in the lag phase during the early 
period of activation. 
4. DISCUSSION 
FUT-175 is a synthetic inhibitor of trypsin-like 
serine proteinases [171. A special feature of this in- 
hibitor is that it strongly inhibits proteinases in- 
volved in the complement system, such as Cl;, Cl;, 
B and D, as well as proteinases involved in 
coagulation, kallikrein-kinin and fibrinolysis 
systems [20]. Its inhibition mechanism is supposed 
to be similar to that of NPGB, since FUT-175 is 
also a derivative of guanidinobenzoate. However, 
the inhibition of Clr by FUT-175 was about 
4-times that by NPGB [17,21]. The reason for this 
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Volume 172, number 2 FEBS 
is unknown, but possibly the amidinonaphthol 
moiety of FUT-175 participates in the inhibition. 
Here, we investigated the effect of FUT-175 on the 
activation of Clr. Results indicated that FUT-175 
was about 5-times more effective than NPGB. This 
result is consistent with their relative inhibitions of 
CG. 
In inhibition of the activation of Clr, NPGB has 
been reported to interact with intermediary Clr 
(Clr*) formed during the activation process, and so 
its inhibition of the activation to Clr is reversible 
[8]. The active site in Clr* is supposed to be 
generated by a conformational change occurring in 
the early phase of activation, but is no positive 
evidence that formation of the active site involves 
a conformational change of Clr proenzyme, and 
the incorporation of an inhibitor into the active 
site formed has not been proposed. Accordingly, 
proof of the above hypothesis requires determina- 
tion of the amount of active site formed in Clr*. 
When FUT-175 is used as inhibitor, the release 
of amidinonaphthol with the acylation of an active 
serine residue by the guanidinobenzoate moiety 
can be observed. Since amidinonaphthol emits 
strong fluorescence, by measuring the fluorescence 
of amidinonaphthol formed by the reaction bet- 
ween FUT-175 and Clr*, the amount of active site 
formed can be determined. Results indicated that 
release of amidinonaphthol was equimolar with 
the amount of Clr used in the early period (about 
10 min) of incubation, in which the activation to 
Clf was slight (about 5%). This strongly suggests 
that Clr* already has a complete active site. 
Recently, experiments with a hydrophobic fluores- 
cent probe showed that, although Clr has a single 
chain, its conformation changes rapidly during the 
early period of incubation [16]. These results can 
be explained by supposing that the rapid confor- 
mational change of Clr in the early period of in- 
cubation causes formation of the complete active 
site, and that interaction between this active site 
and the inhibitor suppresses further activation to 
c1r. 
Recently it was reported that activation of Clr 
proceeded by a two-step reaction: first an in- 
tramolecular catalytic process catalyzed by Clr 
proenzyme itself, and then an intermolecular eac- 
tion catalyzed by Clr [14]. This mechanism may 
well explain the kinetics of autoactivation of Clr, 
although there are several reports suggesting that 
162 
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Clr alone cannot activate Clr [8,9]. Our finding 
that an intermediary Clr (Clr*) already has a com- 
plete active site supports the idea of a two-step 
reaction in autoactivation of Clr. However, it is 
not clear whether the conversion of Clr* to Clr in 
the first step proceeds by an intramolecular reac- 
tion catalyzed by Clr* itself or by an inter- 
molecular reaction. 
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